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Abstract
There has been a large increase in basic science activity in cell therapy and a growing portfolio of cell therapy trials. 
However, the number of industry products available for widespread clinical use does not match this magnitude of 
activity. We hypothesize that the paucity of engagement with the clinical community is a key contributor to the lack of 
commercially successful cell therapy products. To investigate this, we launched a pilot study to survey clinicians from five 
specialities and to determine what they believe to be the most significant barriers to cellular therapy clinical development 
and adoption. Our study shows that the main concerns among this group are cost-effectiveness, efficacy, reimbursement, 
and regulation. Addressing these concerns can best be achieved by ensuring that future clinical trials are conducted to 
adequately answer the questions of both regulators and the broader clinical community.
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Introduction
Cellular therapies offer significant potential to treat multi-
ple diseases and injuries, many of which are poorly 
addressed by the current standards of care. These ground-
breaking therapies have grown out of, and to some extent 
encompass, concepts from both tissue engineering (TE) 
and regenerative medicine (RM), first described in the 
1980s1 and 1990s,2 respectively (see Table 1 for defini-
tions). Despite significant developments in these areas, 
there are still relatively few commercially available prod-
ucts in widespread use that utilize the principles of these 
two fields, as seen in Table 2 (adapted from French et al.3).
The most widely used products have been in the TE and 
bone marrow transplant areas, yet as outlined by Jaklenec 
et al.,4 the TE space has experienced a fitful tenure over the 
last 25 years. The failure of products to live up to the prom-
ise held during development has negatively impacted upon 
the willingness of clinicians to embrace these technolo-
gies, consequently resulting in a lack of long-term efficacy 
data.5 More recently though the sector has overcome some 
of these early disappointments facilitated by early evi-
dence of clinical success, investor appetite, and expanded 
research funding.6–8
It is important to recognize that there is a lack of con-
sistency in the use of terms such as “cell-based therapies,” 
“regenerative medicine,” “tissue engineering,” and “stem 
cell therapy,” with some treating the terms as distinct enti-
ties, while others use them synonymously.4 Within this 
article, the term “cellular” or “cell-based therapy” encom-
passes any treatment that involves the use of exogenous 
cells (autologous or allogenic) in an attempt to repair dis-
eased or damaged tissue.
Cell-based therapy progress
The rapid growth of this sector is clearly demonstrated by 
the soaring number of clinical trials that seek to use cell-
based therapies.9,10 Despite this, the number of cell-based 
therapies available in the marketplace has remained fairly 
stagnant.3
To better understand this disparity, we have sought to 
investigate the potential barriers to the clinical develop-
ment and adoption of this class of novel therapeutics as 
perceived by the end users of such therapies, clinicians, 
via an initial pilot study. It is hoped that by successfully 
identifying these root causes, it will be possible to stream-
line and accelerate the process by which potentially useful 
cell-based therapies are developed and then brought into 
mainstream use. We therefore conducted a pilot study at a 
leading hospital in the United Kingdom as a necessary 
and informative basis for future investigations.
Materials and methods
To identify the main barriers to adoption from the point of 
view of clinicians, 50 specialists were approached at a 
leading academic teaching hospital group in the United 
Kingdom, evenly split into the following areas:
•• Cardiology
•• Neurology
•• Ophthalmology
•• Orthopedic Surgery
•• Plastic and Reconstructive Surgery
These specialities were carefully chosen as areas in 
which there has been research and development of cellular 
therapies or in which there is significant contemporary 
interest in basic stem cell science. Historically, Orthopedic 
Surgery has been the trailblazer since autologous chondro-
cyte implantation was first described 20 years ago.11 The 
other clinical specialities have been the focus of cell-based 
therapies in recent years with treatments designed for 
myocardial infarction,12 multiple sclerosis,13 and retinal 
photoreceptor loss.14
Participants were surveyed between July and August of 
2013. Participants were asked about their experience 
using cellular therapeutics and then required to assess 
whether 12 areas were seen as a barrier to cellular treat-
ment use. A copy of the questionnaire is provided in the 
Supplementary Material and the areas covered were as 
follows:
•• Safety
•• Efficacy
•• Clinical trial methodologies
•• Cost-effectiveness
•• Usability
•• Visibility
•• Patient characteristics
•• Patient attitudes and preferences
•• Infrastructure
•• Reimbursement
•• Community
•• Regulation
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A Likert-style scale was used to assess responses. Each 
question was scored on a scale of 1 (No Barrier) to 5 
(Significant Barrier). Responses from the questionnaire 
were averaged across all respondents and within each spe-
ciality and then ranked in order from the smallest per-
ceived barrier to the largest.
The results were analyzed separately by speciality and 
also as a whole for the complete group. Analysis was car-
ried out using Prism 6 (GraphPad Software Inc., San 
Diego, CA, USA).
Results
Responses were obtained from 50 individuals in total with 
10 in each speciality group. The participants had a range of 
knowledge and experience with cell-based therapies as 
shown in Figure 1.
There was no significant difference in the experience 
spread within the individual specialities (Kruskal–
Wallis = 7.7; p = 0.17). The majority of participants had 
some knowledge of the field of cellular therapies although 
very few had actually used them in a clinical setting.
Figure 2 shows the mean level for perceived barrier for 
all respondents and the variation in the mean response for 
each speciality from the group mean. Higher numbers rep-
resent a larger perceived barrier to adoption. The data 
show that the most concerning barriers to clinicians were 
cost-effectiveness and efficacy, followed by regulation, 
reimbursement, and safety. Infrastructure also frequently 
occurred in the top three responses.
Figure 3 shows the average score for each question 
in each group. A heat map has been constructed with 
green being the smallest barrier and red the largest bar-
rier to adoption to help visualize the spread of opinion 
across specialities. Interestingly, a number of notable 
concerns were identified in relation to clinical special-
ity, although due to the sample size of this pilot study, 
further investigation is required. Neurologists identi-
fied patient characteristics as a major barrier to cell 
therapy utilization in comparison to the other four clin-
ical specialities (Figure 3). Ophthalmologists were 
concerned by usability; orthopedic surgeons identified 
clinical trial methods and plastic surgeons efficacy and 
patient preference.
Discussion
The results from our pilot study show that across multiple 
specialities, there is a degree of consistency for which bar-
riers to development and adoption are perceived as the 
largest for cell-based therapies, namely, efficacy and cost-
effectiveness. The remaining barriers perceived to be 
significant do vary between groups with reimbursement, 
safety, regulations, and infrastructure all identified consist-
ently within the highest ranking barriers, as shown in 
Figure 4.
Table 1. Definition of key terms.
Term Definition
Tissue 
engineering
“An interdisciplinary field that applies 
the principles of engineering and the 
life sciences toward the development 
of biological substitutes that restore, 
maintain, or improve tissue function.”38
Regenerative 
medicine
A technique that “replaces or regenerates 
human cells, tissue or organs, to restore 
or establish normal function.”39
Table 2. Cellular therapy products in use.
Medical speciality Company Product Condition
Cardiology FCB Pharmicell Heartcelligram Acute myocardial infarction
Diabetes Organogenesis Dermagraft Diabetic foot ulcers
Diabetes/Vascular 
Disease
Organogenesis Apligraf Venous leg and diabetic 
foot ulcers
Gastroenterology Anterogen Cupistem Crohn’s disease
Maxillofacial Surgery Organogenesis Gintuit Gingival repair
Orthopedics Genzyme Carticel Articular cartilage repair
Orthopedics Medipost Cartistem Articular cartilage repair
Orthopedics NuVasive Osteocel Plus Skeletal defects
Orthopedics Orthofix Trinity Evolution Musculoskeletal defects
Orthopedics TiGenix ChondroCelect Articular cartilage repair
Plastics Avita Medical ReCell Burns/scars
Plastics, Orthopedics, 
Ophthalmology
Japan Tissue 
Engineering
J-TEC Epidermis/Cartilage/
Corneal Epithelium
Burns, cartilage repair, 
ocular repair
Urology Dendreon Provenge Prostate cancer
 Osiris Prochymal Graft-vs-host disease
 Genzyme Epicel Severe burns
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It is no surprise that efficacy poses a considerable bar-
rier in the opinion of those asked, followed closely by 
safety, as the primary aim of the clinician is to treat and 
hopefully cure the patient. Deficiencies in safety and effi-
cacy results can to some extent be explained by the often 
limited understanding of the underlying mechanism of 
action.15 Additionally, heterogeneity in clinical trial struc-
tures, treatment protocols, and results presentation, com-
bined with the limited body of historic patient outcome 
data, further impede clinical decision-making for when 
these treatments may be beneficial.16–19 Data limitations 
are also challenging from a health economics perspective.
In most cases, cellular therapies are significantly more 
expensive than the treatment that they seek to replace.20 
They can, however, potentially offer a longer lasting solu-
tion and the opportunity to regenerate tissue, unlike tradi-
tional treatments.21 It is therefore vital, in both private and 
public provider systems, to ensure that adequate product 
cost-effectiveness is demonstrated to justify appropriate 
reimbursement codes for the entire treatment pathway, 
which in the case of autologous products includes medical 
procedures relating to tissue acquisition.22 As such, it is 
evident that many cell-based therapeutics are likely to 
exhibit different direct and indirect cost structures to 
established non-cell-based products and services,23 in part, 
due to the unique infrastructural demands concerning their 
delivery.
For all healthcare innovations, the requisite delivery 
infrastructure and appropriate regulation(s) are intimately 
linked;24 principally, due to the need to maintain product 
critical quality attributes (CQAs) throughout the entire 
biomanufacturing process from tissue acquisition to 
administration.25–27 Given the interdependence of cellular 
therapies on their bioprocessing environment,28 they are 
highly reliant upon the availability and compliance of 
Current Good Manufacturing Practices (cGMP) laborato-
ries, internal and external to hospital settings, that must 
adhere to strict workflows for provision and manipulation 
of cells and tissues for the safe re-implantation to the 
patient.29 The lack of supporting data for point-of-care 
(POC) processing technologies which avoid the need for 
cGMP laboratories explains, to some extent, the lack of 
clinical confidence in these systems.30,31 Moving forward, 
these systems must therefore be designed such that ease of 
use and safety of the cellular material is paramount and the 
path to approval is clear.32
More generally, clinical trial methodologies were not 
felt to be a large barrier to adoption within our pilot study, 
which may be due to a perception of the rigor with which 
trials are conducted or a lack of concern regarding the 
methodology of clinical trials, yet recent late-stage failures 
intimate that greater caution may be required.33,34 
Interestingly, orthopedics, a speciality in which cell thera-
pies have been more frequently utilized, identified clinical 
trial methodologies as a barrier in comparison to the other 
clinical groups. Usability was of moderate concern to most 
groups which further emphasizes the need to develop tech-
nologies that are easily adopted for a wide variety of clini-
cal settings, ideally with minimal training for support staff, 
such as operating department assistants. Finally, patient 
attitudes and preferences were frequently listed in the 
three smallest barriers to adoption, possibly due to a lack 
of patient awareness as to the available options and/or a 
clinician belief that it may not be worth discussing options 
with patients for which they have limited confidence or 
that are not readily available. It should be noted, however, 
that as this pilot study was performed in the United 
Kingdom, an emphasis with regard to patient attitudes and 
preferences in private payer systems, such as the United 
States, maybe expected to yield different results.
Additionally, the ranking distribution for different issues 
may be due to the variation in previous exposure to these 
treatments. Although there was no significant difference in 
the self-reported level of experience of cellular therapies 
between the groups, there is a great deal of variation in the 
extent to which trials of cell therapy treatments have pene-
trated the various specialities.35 Simply by examining the 
currently available cellular therapies as shown by the 
review undertaken by French et al.,3 very few of these treat-
ments are available within normal clinical practice.
Limitations
The main limitation affecting this study comes from the 
use of a questionnaire and from the sample size of the pilot 
study. It is not possible with this design to ensure that there 
is exactly the same level of understanding of the issues 
being asked about between specialists. This variation in 
understanding will, however, better reflect the understand-
ing of all clinicians rather than use subject experts only. It 
is also not possible to determine the exact nature of the 
reason for which experts attribute a particular score, so 
underlying motivations may be better elicited in future 
studies with the opportunity for qualitative responses. The 
restriction of this pilot study to a single hospital group will 
also skew the conclusions that we have attempted to draw 
Figure 1. Survey participant knowledge and extent of 
familiarity with cell therapy products.
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from the results. Nonetheless, scores obtained were wide-
ranging both between groups and individuals, hence the 
risk of having surveyed a biased subset of specialists was 
likely minimal.
The route ahead
While immense investment into the cell-based therapy 
market has occurred over the last decade,36,37 this increase 
has sadly not been matched by the widespread availability 
of treatments to patients. It is clear that while the scientific 
barriers to the creation and development of effective cellu-
lar therapies are gradually being overcome, another sizable 
potential barrier to broad adoption lies in the attitudes and 
decision-making processes of the clinical community to 
prescribe and recommend such innovative approaches.
Despite the diverse availability of cell-based therapies 
in different clinical specialities, it is clear from this pilot 
study that similar barriers to clinical development and 
adoption are common among all. The majority of these 
barriers related to clinician concern (cost-effectiveness, 
efficacy, and safety) can only be successfully tackled by 
Figure 2. Perceived barriers to clinical development and adoption as identified through pilot questionnaire. Responses are 
presented as the mean for the whole group and then variation in each speciality’s mean response from the group mean. A higher 
score represents a greater perceived barrier.
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conducting well-designed clinical trials that effectively 
address the following areas:
•• Appropriate length of follow-up to ensure that clini-
cal benefits are maintained over a period that is 
clinically relevant. Significant benefits would also 
be gained from identifying short-term indicators 
correlated with long-term outcomes for the indica-
tion in question.
•• Use of a variety of clinical- and laboratory-based 
outcome measures to allow comparison between 
different trials.
•• Current standard of care, where possible, is included 
within the trials as a control arm.
•• Design therapies and trials to enable the regulatory 
issues of different markets to be addressed in an 
efficient manner.
Thoughtful clinical trial design, focused on the above 
criteria and involving the clinicians at an early stage, 
should allow not only effectiveness of a treatment to be 
confirmed but also safety and cost-effectiveness with rela-
tive ease. It should then be possible to address regulatory 
issues in such a way as to minimize delays in bringing 
these innovative treatments to market, and therein reach-
ing the end goal of treating patients suffering with unmet 
medical needs.
It is our intention to progress the findings identified 
in this pilot study by carrying out a further round of 
questioning covering an international set of locations 
and widening the specialities to include others such as 
Ear, Nose, and Throat Surgery and Urology. The sample 
number of the clinicians surveyed will be significantly 
extended. This will, hopefully, allow us to capture a 
broader, and more representative view of the barriers 
that clinicians perceive to be preventing cellular therapy 
use. Findings will then be reviewed by an international 
expert panel to maximize the value of conclusions drawn 
from the data obtained.
Centre for the Advancement of 
Sustainable Medical Innovation 
Translational Stem Cell Consortium
Clinical perspective questionnaire
The Centre for the Advancement of Sustainable Medical 
Innovation (CASMI) Translational Stem Cell Consortium 
(CTSCC) is an international, multi-stakeholder collabo-
ration aiming to provide a global nexus for the efficient 
and sustainable translation of fundamental stem cell sci-
ence into tangible products and services. Due to the 
novel nature of cellular therapies, it is evident that the 
clinical community will play a critical role in their suc-
cessful adoption. As such, it is imperative that we poll 
the opinions of surgical clinicians like yourself in order 
to best address the potential barriers that currently or 
may in the future be impediments to these therapies from 
your perspective.
Section 1: Respondent Background Information
Clinical Specialty: ____________________________
Job Title or Position: __________________________
Extent of Experience with Cellular Therapeutics: 
(Please indicate all that apply)
Please state the reasons that stopped you from using 
cellular therapy (if any):
Figure 3. Heat map of mean response data to perceived 
barriers by clinical speciality. Data are presented as the mean 
response from the polled clinicians.
Figure 4. Frequency with which each barrier appears in 
highest or lowest three perceived barriers (ordered as per “All 
Experts” mean ranking).
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Section 2: Assessment of Barriers to Clinical Adoption
Following an industry review, the following factors have 
been suggested as barriers to the adoption of cellular 
therapeutics. Below please indicate the extent to which 
you believe each case is a potential impediment to their 
clinical success, where 1 = No Barrier(s) and 5 = Significant 
Barrier(s)
1. Safety: Extent of available data concerning product 
safety including the stage of development of under-
lying science and/or characteristics of biomaterials 
utilized in tissue engineering.
2. Efficacy: Extent to which available data concern-
ing product efficacy profiles, including the extent 
to which mechanisms of action, have been pro-
posed and identified.
3. Clinical Trial Methodologies: Quality and rigor of 
clinical trial designs implemented.
4. Cost-Effectiveness: Availability of data to inform 
evaluations of the benefits of cellular therapeutics 
versus standard(s) of care.
5. Usability: Limitations in ease of use.
6. Visibility: Level of awareness of cellular therapeutics 
and their applications within the clinical community.
7. Patient Characteristics: Limitations in the number 
of patients with suitable prognosis to facilitate the 
administration of a cellular therapeutic:
8. Patient Attitudes & Preferences: Level of patient 
familiarity, resistance, or concern around cell thera-
pies, such as concerns regarding “stem cell stigma.”
9. Infrastructure: Uncertainties in clinical delivery 
including available expertise, equipment, “chain(s) 
of custody” control, or others.
10. Reimbursement: Relative provision and/or knowl-
edge of reimbursement pathways compared to rou-
tine therapies.
11. Community: Impact of peer opinion(s) on clinical 
decision-making.
12. Regulation: Level of certainty or ambiguity in the 
regulatory pathway including the regulatory classifi-
cation of cellular therapeutics and/or responsibilities 
of clinical practitioners and fear of malpractice.
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